Alberta Health Services

Arch Biopartners Inc. announces Alberta Health Services approval for Phase II trial of LSALT peptide for preventing cardiac surgery-associated acute kidney injury (CS-AKI). The trial, targeting 240 patients, aims to evaluate AKI incidence within seven days post-surgery using KDIGO criteria. Recruitment begins in September at University of Calgary, Toronto General Hospital, and St. Michael's Hospital, with additional sites in Turkey.